瑞图生物是一家专注于人工智能与医学诊断深度融合的AI生物医学初创公司，近日宣布成功完成亿元级别的B2轮融资。此轮融资由国科投资、国内知名基金领投，深投控资本参与投资，点石资本担任独家财务顾问。
瑞图生物一直致力于利用先进的人工智能技术改进医学诊断，为医疗行业带来革命性的变革。随着此次融资的成功，公司将进一步加强在AI生物医学领域的研发力度，推动更多创新技术走向市场。
此次融资将用于持续优化瑞图生物的产品线，包括AI辅助诊断、医疗影像分析等方向。此外，公司还将扩大业务规模，加强与医疗机构、科研院所的合作，为我国医疗事业的发展贡献力量。
英文翻译：
News title: AI-based Biomedical Startup Ruitu Biotechnology Secures Over 100 Million Yuan in Series B Financing
Keywords: Ruitu Biotechnology, AI Medicine, Financing
News content:
Ruitu Biotechnology, an AI-based biomedical startup focusing on the deep integration of artificial intelligence and medical diagnosis, has recently announced the successful completion of a Series B financing of over 100 million yuan. The round of financing was led by State Key Investment and other domestic renowned funds, with participation from Shenzhen Investment Holdings Capital and exclusive financial advisory services provided by Dianshi Capital.
Ruitu Biotechnology has been dedicated to utilizing advanced artificial intelligence technology to revolutionize the medical diagnostic field. With the success of this financing, the company will further strengthen its research and development in the AI biomedical field and bring more innovative technologies to the market.
The financing will be used to continuously optimize Ruitu Biotechnology’s product line, including AI-assisted diagnosis and medical imaging analysis. In addition, the company will expand its business scale, strengthen cooperation with medical institutions and research institutes, and contribute to the development of China’s medical industry.
【来源】https://www.vbdata.cn/1518942969
Views: 1